When Diabetics’ Kidneys Fail Silently: The Albumin-Negative Kidney Disease That May Be a Different Condition Entirely

For decades, one laboratory number has dominated how doctors judge whether diabetes is destroying a patient’s kidneys: the amount of albumin spilling into the urine. Albuminuria has served as the canonical early warning sign of diabetic kidney disease, the leading cause of kidney failure worldwide, and its presence or absence has shaped screening schedules, drug choices, and prognosis discussions in virtually every clinic on earth. But a growing body of evidence suggests that a substantial minority of diabetic patients develop genuine kidney damage without ever leaking significant albumin, a condition known as non-albuminuric diabetic kidney disease, or NADKD. A new retrospective cohort study from Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, published in BMC Endocrine Disorders, now offers one of the most detailed portraits yet of this enigmatic subgroup, and its findings challenge several long-held assumptions about how diabetic kidney disease progresses and who is truly at risk.

The research team, led by Tongkai Wu, Jin Yu, Yinfeng Chen, Dongrong Yu, and Jun Ni, assembled a cohort of 905 patients with diabetic kidney disease whose baseline estimated glomerular filtration rate, or eGFR, sat between 15 and just under 60 mL/min/1.73 m², the range defining moderate to severe chronic kidney disease. Enrolment stretched from June 2008 to April 2024, giving the study more than fifteen years of real-world clinical data drawn from a single center. Using the urine albumin-to-creatinine ratio, the standard metric for classifying albuminuria, the researchers divided patients into 176 with NADKD and 729 with the conventional albuminuric form of diabetic kidney disease. Because the two groups differed in many baseline characteristics, the investigators applied propensity score matching in a one-to-one fashion, a statistical technique that pairs patients across groups with similar overall risk profiles, ultimately yielding 151 well-balanced patients in each arm with a median age of 73 years.

The comparison revealed a metabolic fingerprint that sets NADKD apart in striking ways. Patients in the non-albuminuric group had higher serum albumin levels but lower fasting blood glucose, lower total cholesterol, lower glycated hemoglobin, and a lower triglyceride-glucose index, a composite marker of insulin resistance. In plain terms, these patients carried a milder metabolic derangement than their albuminuric counterparts, yet their kidneys had still declined to the same functional territory. That paradox is precisely what makes NADKD clinically perplexing: if chronic hyperglycemia and dyslipidemia drive kidney injury in diabetes, why do some patients with comparatively better metabolic control lose kidney function while their urine remains essentially albumin-free?

One of the study’s most eye-catching findings points toward an answer that lies outside the kidney itself. Nearly sixty percent of the NADKD patients, 59.6 percent, had macrovascular disease, meaning clinically manifest atherosclerotic conditions such as coronary artery disease, cerebrovascular disease, or peripheral arterial disease, compared with only 39.7 percent of the albuminuric group, a difference that reached statistical significance at P equals 0.001. This inverted burden, heavier vascular disease in the group with lighter microvascular footprints, suggests that non-albuminuric diabetic kidney disease may not simply be an early or attenuated version of classic diabetic nephropathy but a biologically distinct entity in which large-vessel pathology and ischemic injury to kidney tissue play a proportionally larger role than the microvascular mechanisms classically blamed for diabetic kidney failure.

The prognostic implications of that distinction are substantial. Kaplan-Meier survival analysis, the standard method for tracking event-free survival over time, showed significantly better renal survival in the NADKD group, with a P value below 0.001. The annual rate of eGFR decline told the same quantitative story: patients with non-albuminuric disease lost kidney function at 0.747 mL/min/1.73 m² per year on average, whereas albuminuric patients declined at 3.224 mL/min/1.73 m² per year, more than four times faster. Slippage of that magnitude compounds mercilessly; a patient losing three-plus units annually from a baseline of 40 will typically cross the threshold toward dialysis within a decade, while a slower decliner may never reach end-stage disease within their lifetime. All-cause mortality, intriguingly, did not differ significantly between the groups, with a P value of 0.054 that narrowly missed conventional significance, hinting that while the kidneys fare differently, overall survival risk may be comparable once the vascular burden is accounted for.

To move from description to prediction, the researchers built a multivariable Cox proportional hazards model, the workhorse tool for identifying independent risk factors for time-to-event outcomes. In that analysis, macrovascular disease emerged as an independent risk factor for composite renal outcomes, carrying a hazard ratio of 4.19 with a 95 percent confidence interval spanning 1.45 to 12.09 and a P value of 0.008. A hazard ratio above four is clinically meaningful: after adjusting for other variables, patients with macrovascular disease faced more than quadruple the instantaneous risk of a adverse renal event compared to those without. The final parsimonious model contained just four variables, age, sex, baseline eGFR, and macrovascular disease, an appealingly simple set that any nephrologist or endocrinologist could assemble from a routine clinic visit.

The performance statistics of that model were reported with a methodological rigor that deserves attention. The apparent concordance index, or C-index, a measure of how well the model ranks risk across patients, reached 0.762. Because apparent performance in the development dataset tends to be optimistically biased, the team applied bootstrap internal validation, resampling the data 1,000 times to estimate and subtract that optimism. The optimism-corrected C-index settled at 0.744, still comfortably in the range considered acceptable to good for clinical prediction models. Time-dependent analyses added further support: the area under the receiver operating characteristic curve for predicting renal outcomes at three years was 0.828, and at five years it was 0.745. In practical terms, the model correctly discriminates high-risk from low-risk patients well enough to justify early intensified monitoring in those flagged as vulnerable, particularly those with documented macrovascular disease.

The conceptual takeaway is potentially practice-changing. Screening algorithms built around albuminuria may systematically miss patients whose kidneys are quietly deteriorating without a protein leak, delaying both diagnosis and the initiation of kidney-protective therapies. The study’s authors argue that NADKD represents a distinct subtype of diabetic kidney disease, one characterized by a heavier macrovascular burden and a slower but real trajectory of renal decline. That framing carries a direct clinical message: in a patient with diabetes and falling eGFR, a normal urine albumin-to-creatinine ratio should reassure nobody. Instead, the presence of coronary, cerebral, or peripheral atherosclerosis in such patients should itself be read as a renal risk signal, and serial eGFR monitoring should be treated as the primary surveillance tool for this population in the way albumin measurements have long been for others.

As with all single-center retrospective studies, caveats apply. The cohort came from one hospital in Hangzhou, China, and the retrospective design means classification depended on the quality of routine clinical documentation rather than protocolized assessments; residual confounding by unmeasured variables can never be fully excluded even with propensity matching. Kidney biopsies, the diagnostic gold standard that would confirm whether the pathology of NADKD truly differs at the tissue level, were not part of the analysis, so the mechanistic interpretation, that large-vessel ischemia substitutes for microvascular injury, remains a well-supported hypothesis rather than a histologically proven fact. The prediction model, validated internally by bootstrap but not yet in an external independent cohort, will need confirmation in multi-center populations before it can be embedded in guidelines.

Nevertheless, the study lands at a moment when the clinical stakes of diabetic kidney disease are rising sharply. Global diabetes prevalence continues to climb, kidney replacement therapy remains enormously expensive, and newly available kidney-protective drugs, from SGLT2 inhibitors to non-steroidal mineralocorticoid receptor antagonists, work best when started early. Identifying which patients need those therapies most urgently, including the non-albuminuric minority that traditional screening overlooks, could translate directly into preserved kidney function and avoided dialysis. If follow-up studies confirm that macrovascular disease reliably stratifies renal risk in NADKD, the humble urine dipstick may finally have to share its throne with a stethoscope, an electrocardiogram, and a routinely calculated eGFR slope, a small shift in workflow with the potential to change outcomes for millions of patients whose kidneys fail without ever leaking a trace of albumin.

Subject of Research: Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease in patients with reduced kidney function

Article Title: Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study

Article References: Wu, T., Yu, J., Chen, Y., Yu, D., & Ni, J. (2026). Clinical characteristics and prognosis of non-albuminuric diabetic kidney disease: a single-center retrospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02646-8

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02646-8

Keywords: diabetic kidney disease, non-albuminuric diabetic kidney disease, chronic kidney disease, macrovascular disease, eGFR decline, albuminuria, renal prognosis, risk prediction model, propensity score matching, BMC Endocrine Disorders, diabetic nephropathy, retrospective cohort study